| GRMN |
Report |
Q2 2026 revenue |
BEAT |
pred ~$1.97B vs. cons $1.94B |
MEDIUM |
| GRMN |
Report |
Q2 2026 pro forma EPS |
BEAT |
pred ~$2.37 vs. cons $2.29 |
MEDIUM |
| GRMN |
Report |
Q2 2026 operating margin |
IN-LINE |
pred ~25.7% vs. cons 25.5% |
LOW |
| GRMN |
Guide |
Revenue guidance |
BETTER |
guide ~$8.00B vs. cons $7.99B (FY2026) |
MEDIUM |
| GRMN |
Guide |
Pro forma EPS guidance |
BETTER |
guide ~$9.60 vs. cons $9.58 (FY2026) |
MEDIUM |
| GRMN |
Guide |
Operating margin guidance |
BETTER |
guide ~25.7% vs. cons 25.6% (FY2026) |
LOW |
| GRMN |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.2% |
— |
LOW |
| GRMN |
Return |
5-day cumulative residual |
-3.8% (FOLLOW-THROUGH) |
A Q2 EPS beat of ~$2.37 vs. cons $2.29 is likely offset by FY2026 guidance of ~$9.60 vs. cons $9.58, implying H2 EPS of only ~$5.15 vs. pre-print cons ~$5.21; the resulting out-period estimate cuts should extend the initial weakness. |
MEDIUM |